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Abstract 
The human gut microbiome encodes 4.8 million genes, some of which  are expected to 
create a wealth of catalytic enzymes functions in the gastrointestinal (GI) tract.  We have focused 
on gut microbial beta-glucuronidase (GUS) enzymes because they cause dose-limiting GI 
toxicity of many drugs, including chemotherapeutics.  We have created an atlas of all the GUS 
proteins in the human gut microbiome, termed the GUSome.  A focal question asks how 
selective inhibition of gut microbial GUS enzymes can alleviate the toxic side effects of 
chemotherapeutics and pain medicines.    Here we show that novel analogs of UNC10201652, a 
previously characterized GUS inhibitor, block the activity of E. coli GUS, S. agalactiae GUS, 
and C. perfringens GUS.  Each of these enzymes contain an active site loop (Loop 1) that plays a 
key role in processing small-molecule drug-glucuronides.  Kinetic analysis revealed that the 
inhibitors display differential  inhibition across the distinct GUS enzymes examined.  We show 
that GUS enzymes are differentially inhibited by analogs of UNC10201652 by characterizing the 
distinct substrate-dependent slow-binding kinetics of these piperazine-dependent inhibitors.  The 
characterization of these piperazine-containing GUS inhibitors  may improve the outcomes of 
essential chemotherapeutics. 
 
Introduction 
The human gastrointestinal (GI) tract is colonized with trillions of bacteria.  Bacteria 
express β-glucuronidase (GUS) enzymes that promote the toxicity of cancer medication in the 
gut by metabolizing these and other drug substrates (Pollet, et al., 2017 & Wallace, et al., 
2010).  Uridine 5'-diphospho-glucuronosyltransferases (UGTs) in the liver inactivate drugs via 
the attachment of glucuronic acid, which marks these drugs for removal from the body.  By 
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cleaving glucuronate from the chemotherapy drug, the GUS enzyme reactivates it, which 
promotes the GI toxicity these drugs display (Pellock & Redinbo, 2017 & Wallace, et al., 
2010).  We have previously developed GUS inhibitors that demonstrate the impact these 
enzymes have on the body and drug toxicity levels, with Inhibitor 1 and Inhibitor 9 being the two 
most effective.  The main inhibitor, UNC10201652, was discovered through a High Throughput 
Screen involving the reaction with a GUS enzyme and PNPG substrate.  Through a Structure 
Activity Relationship Study, four analogs were found that shared a similar structure that included 
a piperazine-ring.  One analog, UNC10206579, was used for this project and is of importance 
because we are looking at the substrate-dependent kinetics of piperazine-dependent inhibitors. 
It was determined that the proteins in the GUSome, or GUS Galaxy, fell into 6 different 
classes based on their active site loop structure (Fig. 1).  We chose the four enzymes of interest 
for this project because they are all Loop 1 enzymes.  The active site loop is important because it 
plays a key role in processing small-molecule drug-glucuronides (Biernat et al., 2019).  The 
project involves GUS enzymes that have been sampled from a variety of clades of microbiota 
from the Sequence Similarity Network (Fig. 1).  
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Figure 1.  Sequence Similarity Network of β-glucuronidase (GUS) enzymes.  Proteins are 
clustered into clades based on sequence identity and functionality. On this map, each circle or 
triangle represents a single protein sequence, while the lines connecting the shapes represent a 
shared sequence segment. 
  
The human gut microbiome plays a key role in the GI toxicity of chemotherapeutics and pain 
medicines.  For example, the GI toxicity of the  key chemotherapy drug Irinotecan is mediated 
by gut microbial GUS enzymes.  The liver activates Irinotecan, a pro-drug that is converted to 
SN-38.  This is the active molecule that can then be glucuronidated in the liver by UGTs, after 
which it is secreted into the gut where it can be metabolized by bacterial GUS enzymes.  The 
GUS enzymes cleave the glucuronide from SN-38-G, reactivating SN-38 in the GI tract which 
promotes dose-limiting gut toxicity (Fig. 2).  The central hypothesis is that selective inhibition of 
gut microbial GUS enzymes will alleviate the toxic side effects of chemotherapeutics and pain 
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medicines. Here we detail kinetic inhibition assays that were utilized to determine the ability of 
novel piperazine-containing inhibitors to block three distinct GUS enzymes. 
 
Figure 2. Bacterial GUS reactivates and toxifies the chemotherapeutic Irinotecan. 
  
Methods 
Kinetic Assays Continuous kinetic assays with fluorescent substrate 4-methyl umbelliferyl 
glucuronide (4-MUG) were performed to assess GUS inhibition.  We first analyzed the inhibition 
kinetics of  UNC10206579, a chemical analog of the previously characterized GUS inhibitor 
UNC10201652, against E. coli GUS, S. agalactiae GUS, and C. perfringens GUS (Fig. 3).   
   
UNC10201652     UNC10206579 
Figure 3. Original inhibitor and analog from the Structure Activity Relationship (SAR) Study. 
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For the E. coli activity assay, 900 mM of 4-MUG substrate and 10 nM of E. coli GUS 
enzyme were used.  The 10 nM enzyme was diluted in 1x buffer (25 nM NaCl, 25 nM HEPES) 
at pH 7.5.  The range of UNC10206579 inhibitor concentrations utilized for kinetic analysis were 
determined from previously collected IC50 values and all were diluted in 10% DMSO for a final 
of 1% DMSO in the kinetic assay (Table 1).  The continuous kinetic assay contained ddH2O, 10x 
buffer (250 nM NaCl, 250 nM HEPES) at pH 7.5, E. coli GUS enzyme, and UNC10206579 
inhibitor (5 µL each), before incubating at 37°C for five minutes.  After incubation, 30 µL 4-
MUG substrate was added to initiate the reaction and the plate was immediately read by the 
BMG Labtech PHERAstar Plate Reader.  A COSTAR 96 Microplate was set to a focal height of 
6.8 mm.  A FI 350 450 Optic module was set to scan at a wavelength of 250 nm.  Prior to the 
first plate reader cycle, the plate was shaken at 700 rpms for 3 seconds.  This protocol was 
repeated for S. agalactiae GUS and C. perfringens GUS but with different UNC10206579 
inhibitor concentrations (shown in Table 1). 
 
 
 
Table 1. Inhibitor UNC10206579 Concentration Range for Inhibition Assays 
GUS Enzyme Inhibitor Concentration Range (nM) 
E. coli 60 - 160 
S. agalactiae 70 – 160 
C. perfringens 5 - 35 
 
 7 
Data Analysis Activity over time data (in fluorescence units) was recorded for each assay.  It 
was fit by non-linear regression analysis in MATLAB, using the irreversible outlier program, to 
generate the kobs, vi, and R2 values for each replicate involved in a single assay.  The averaged kobs 
values from each replicate were plotted against the inhibitor concentrations, with the slope of the 
line of best fit representing the inactivation (ki/KI) or slow-binding (k3/KI) efficiencies. 
  
Results 
We observed dose-dependent inhibition for all enzyme-inhibitor pairs examined (Fig. 4). 
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Figure 4. Enzyme activity progress curves from one replicate of E. coli GUS + UNC10206579. 
  
E. coli GUS inhibition analysis resulted in an average slow-binding efficiency of 17,000 M-1s-1 
(Table 2, Fig. 5).   
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Table 2. E. coli GUS + UNC10206579 analysis values 
  
 
Figure 5. E. coli GUS + UNC10206579 Inhibitor Concentration vs kobs to give the slow-binding 
efficiency (slope), with error bars representing the variance between data collected. 
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S. agalactiae GUS inhibition analysis resulted in a higher average slow-binding efficiency of 
113,000 M-1s-1 (Table 3, Fig. 6).   
Table 3. S. agalactiae GUS + UNC10206579 analysis values 
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Figure 6. S. agalactiae GUS + UNC10206579 Inhibitor Concentration vs kobs to give the slow-
binding efficiency (slope), with error bars representing the variance between data collected. 
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C. perfringens GUS inhibition analysis resulted in a higher average slow-binding efficiency of 
227,000 M-1s-1 (Table 4, Fig. 7).   
Table 4.  C. perfringens GUS + UNC10206579 analysis values 
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Figure 7. C. perfringens GUS + UNC10206579 Inhibitor Concentration vs kobs to give the slow-
binding efficiency (slope), with error bars representing the variance between data collected. 
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Discussion and Conclusions 
Continuous kinetic fluorescence assays were completed to determine the slow-binding 
efficiencies for the interaction between loop 1 GUS enzymes and piperazine ring-containing 
inhibitor UNC10206579.  S. agalactiae GUS had a much greater slow-binding efficiency than E. 
coli GUS, meaning that inhibition of Sa GUS by UNC10206579 was more effective.  C. 
perfringens GUS had the highest slow-binding efficiency, suggesting that it was inhibited more 
effectively by UNC10206579 than both EcGUS and SaGUS.  This indicates inhibitor potency 
varies among enzymes.  The collected data demonstrates that GUS enzymes are differentially 
inhibited by this analog, and there are distinct substrate-dependent slow-binding kinetics of these 
inhibitors.  Due to the large percent error for the Cp GUS calculations, more replicates should be 
completed to account for said error. 
Future directions of this project include the continuation of UNC10206579 assays with E. 
eligens GUS.  Upon completion, we would move on to complete inhibition assays with the same 
four enzymes, except with other analogs of the original UNC10201652 found in the SAR study 
(Fig. 8). 
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Figure 8. Original inhibitor, UNC10201652, and analogs for future research from the SAR 
Study. 
  
Development of these GUS inhibitors could be used as potential therapies that would allow 
cancer patients to undergo chemotherapy while blocking the drugs’ toxic side effects. 
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